224 related articles for article (PubMed ID: 22945263)
1. Spatiotemporal control of microRNA function using light-activated antagomirs.
Connelly CM; Uprety R; Hemphill J; Deiters A
Mol Biosyst; 2012 Nov; 8(11):2987-93. PubMed ID: 22945263
[TBL] [Abstract][Full Text] [Related]
2. Control of oncogenic miRNA function by light-activated miRNA antagomirs.
Connelly CM; Deiters A
Methods Mol Biol; 2014; 1165():99-114. PubMed ID: 24839022
[TBL] [Abstract][Full Text] [Related]
3. Lentivirus-mediated antagomir expression for specific inhibition of miRNA function.
Scherr M; Venturini L; Battmer K; Schaller-Schoenitz M; Schaefer D; Dallmann I; Ganser A; Eder M
Nucleic Acids Res; 2007; 35(22):e149. PubMed ID: 18025036
[TBL] [Abstract][Full Text] [Related]
4. Silencing of microRNAs in vivo with 'antagomirs'.
Krützfeldt J; Rajewsky N; Braich R; Rajeev KG; Tuschl T; Manoharan M; Stoffel M
Nature; 2005 Dec; 438(7068):685-9. PubMed ID: 16258535
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA Expression Is Altered in an Ovalbumin-Induced Asthma Model and Targeting miR-155 with Antagomirs Reveals Cellular Specificity.
Plank MW; Maltby S; Tay HL; Stewart J; Eyers F; Hansbro PM; Foster PS
PLoS One; 2015; 10(12):e0144810. PubMed ID: 26693910
[TBL] [Abstract][Full Text] [Related]
6. Specificity, duplex degradation and subcellular localization of antagomirs.
Krützfeldt J; Kuwajima S; Braich R; Rajeev KG; Pena J; Tuschl T; Manoharan M; Stoffel M
Nucleic Acids Res; 2007; 35(9):2885-92. PubMed ID: 17439965
[TBL] [Abstract][Full Text] [Related]
7. miRNA Expression profile after status epilepticus and hippocampal neuroprotection by targeting miR-132.
Jimenez-Mateos EM; Bray I; Sanz-Rodriguez A; Engel T; McKiernan RC; Mouri G; Tanaka K; Sano T; Saugstad JA; Simon RP; Stallings RL; Henshall DC
Am J Pathol; 2011 Nov; 179(5):2519-32. PubMed ID: 21945804
[TBL] [Abstract][Full Text] [Related]
8. Temporal and spatial regulation of microRNA activity with photoactivatable cantimirs.
Zheng G; Cochella L; Liu J; Hobert O; Li WH
ACS Chem Biol; 2011 Dec; 6(12):1332-8. PubMed ID: 21977972
[TBL] [Abstract][Full Text] [Related]
9. Targeting respiratory diseases using miRNA inhibitor based nanotherapeutics: Current status and future perspectives.
Mehta M; Satija S; Paudel KR; Malyla V; Kannaujiya VK; Chellappan DK; Bebawy M; Hansbro PM; Wich PR; Dua K
Nanomedicine; 2021 Jan; 31():102303. PubMed ID: 32980549
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of miR-155 in MCF-7 breast cancer cell line by gold nanoparticles functionalized with antagomir and AS1411 aptamer.
Kardani A; Yaghoobi H; Alibakhshi A; Khatami M
J Cell Physiol; 2020 Oct; 235(10):6887-6895. PubMed ID: 32003016
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of anti-miRNA oligonucleotides (AMOs) on A549 cell growth.
Fei J; Lan F; Guo M; Li Y; Liu Y
J Drug Target; 2008 Nov; 16(9):688-93. PubMed ID: 18982517
[TBL] [Abstract][Full Text] [Related]
12. Lentivirus-mediated antagomir expression.
Surdziel E; Eder M; Scherr M
Methods Mol Biol; 2010; 667():237-48. PubMed ID: 20827538
[TBL] [Abstract][Full Text] [Related]
13. LNA-modified oligonucleotides mediate specific inhibition of microRNA function.
Ørom UA; Kauppinen S; Lund AH
Gene; 2006 May; 372():137-41. PubMed ID: 16503100
[TBL] [Abstract][Full Text] [Related]
14. Comparison of different chemically modified inhibitors of miR-199b in vivo.
Duygu B; Juni R; Ottaviani L; Bitsch N; Wit JBM; de Windt LJ; da Costa Martins PA
Biochem Pharmacol; 2019 Jan; 159():106-115. PubMed ID: 30452907
[TBL] [Abstract][Full Text] [Related]
15. Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs.
Nguyen DD; Chang S
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29280958
[TBL] [Abstract][Full Text] [Related]
16. Antagonizing Increased
Vangoor VR; Reschke CR; Senthilkumar K; van de Haar LL; de Wit M; Giuliani G; Broekhoven MH; Morris G; Engel T; Brennan GP; Conroy RM; van Rijen PC; Gosselaar PH; Schorge S; Schaapveld RQJ; Henshall DC; De Graan PNE; Pasterkamp RJ
J Neurosci; 2019 Jun; 39(26):5064-5079. PubMed ID: 31015341
[TBL] [Abstract][Full Text] [Related]
17. miRNA and cancer; computational and experimental approaches.
Tutar Y
Curr Pharm Biotechnol; 2014; 15(5):429. PubMed ID: 25189575
[TBL] [Abstract][Full Text] [Related]
18. Optochemical control of deoxyoligonucleotide function via a nucleobase-caging approach.
Liu Q; Deiters A
Acc Chem Res; 2014 Jan; 47(1):45-55. PubMed ID: 23981235
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA expression profile of the hippocampus in a rat model of temporal lobe epilepsy and miR-34a-targeted neuroprotection against hippocampal neurone cell apoptosis post-status epilepticus.
Hu K; Xie YY; Zhang C; Ouyang DS; Long HY; Sun DN; Long LL; Feng L; Li Y; Xiao B
BMC Neurosci; 2012 Sep; 13():115. PubMed ID: 22998082
[TBL] [Abstract][Full Text] [Related]
20. miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency.
Lu Y; Hippen KL; Lemire AL; Gu J; Wang W; Ni X; Ranganathan P; Levine BL; Riley JL; June CH; Turka LA; Munn DH; Garzon R; Lu L; Blazar BR
Blood; 2016 Sep; 128(10):1424-35. PubMed ID: 27485827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
